Alemtuzumab in a Large Real-Life Cohort: Interim Baseline Data of the TREAT-MS Study

Alemtuzumab in a Large Real-Life Cohort: Interim Baseline Data of the TREAT-MS Study

The non-interventional long-Term study foR obsErvAtion of Treatment with alemtuzumab in active relapsing–remitting MS (TREAT-MS) study collects the so far largest real-life cohort regarding utilization, long-term effectiveness, and safety of alemtuzumab, a humanized monoclonal antibody directed agai...

Full description

Bibliographic Details
Main Authors:	Tjalf Ziemssen, Frank Hoffmann, Stephan Richter, Ulrich Engelmann, Robin White
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-08-01
Series:	Frontiers in Neurology
Subjects:	alemtuzumab non-interventional study risk-management plan Germany real world data multiple sclerosis
Online Access:	https://www.frontiersin.org/articles/10.3389/fneur.2021.620758/full

Similar Items

Clinical efficacy and safety of alemtuzumab in postmarketing practice
by: N. V. Khachanova
Published: (2019-06-01)

Results of treatment with alemtuzumab in a Spanish cohort of patients with multiple sclerosis in the real world: The RealMS study
by: Sara Eichau, et al.
Published: (2023-03-01)

Meccanismo d’azione dei farmaci più recenti, Teriflunomide e Alemtuzumab e implicazioni terapeutiche
by: Francesco Patti
Published: (2015-11-01)

A case of alemtuzumab-induced thyroid disease with a fluctuating course
by: Sarah Ali Alghamdi, et al.
Published: (2023-01-01)

Listeria Meningitis with Aspergillosis After Alemtuzumab Treatment
by: Ahmet Kasım Kılıç, et al.
Published: (2022-03-01)

Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis
by: Trygve Holmøy, et al.
Published: (2019-08-01)

Clinical case of COVID-19 in a patient treated with alemtuzumab
by: E. V. Popova
Published: (2021-12-01)

The Meaning of Immune Reconstitution after Alemtuzumab Therapy in Multiple Sclerosis
by: Simona Rolla, et al.
Published: (2020-06-01)

Effects of Alemtuzumab on (Auto)antigen-Specific Immune Responses
by: Clara Hilger, et al.
Published: (2020-10-01)

A case of Alemtuzumab-induced neutropenia in multiple sclerosis in association with the expansion of large granular lymphocytes
by: A. G. Vakrakou, et al.
Published: (2018-10-01)

Restoration of regulatory B cell deficiency following alemtuzumab therapy in patients with relapsing multiple sclerosis
by: Yeseul Kim, et al.
Published: (2018-10-01)

Efficacy and Safety of Alemtuzumab in Patients of African Descent with Relapsing-Remitting Multiple Sclerosis: 8-Year Follow-up of CARE-MS I and II (TOPAZ Study)
by: Annette F. Okai, et al.
Published: (2019-10-01)

Alemtuzumab-Related Lymphocyte Subset Dynamics and Disease Activity or Autoimmune Adverse Events: Real-World Evidence
by: Elisabetta Signoriello, et al.
Published: (2023-02-01)

Listeria monocytogenes infection associated with alemtuzumab – - a case for better preventive strategies
by: Trygve Holmøy, et al.
Published: (2017-04-01)

Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings
by: Krista Barclay, et al.
Published: (2019-03-01)

Inclusion Body Myositis Treated with Alemtuzumab
by: Juliana Sá, et al.
Published: (2019-12-01)

Product review on MAbs (alemtuzumab and ocrelizumab) for the treatment of multiple sclerosis
by: Tereza Gabelić, et al.
Published: (2021-11-01)

Role of B Cell Profile for Predicting Secondary Autoimmunity in Patients Treated With Alemtuzumab
by: Paulette Esperanza Walo-Delgado, et al.
Published: (2021-10-01)

The budgetary impact of alemtuzumab in multiple sclerosis in Quito, Ecuador. Payer’s perspective
by: Luis J. Pastor-Quirós, et al.
Published: (2021-10-01)

Alemtuzumab Improves Cognitive Processing Speed in Active Multiple Sclerosis—A Longitudinal Observational Study
by: Ester Riepl, et al.
Published: (2018-01-01)

Trans-Endothelial Migration of Memory T Cells Is Impaired in Alemtuzumab-Treated Multiple Sclerosis Patients
by: Kristy Nguyen, et al.
Published: (2022-10-01)

Highly active RRMS and ocrelizumab after failure of alemtuzumab therapy
by: Martin Vališ, et al.
Published: (2020-05-01)

Case Report: Adult Still’s Disease in an Alemtuzumab-Treated Multiple Sclerosis Patient
by: Julia Krämer, et al.
Published: (2020-08-01)

Repopulation of T, B, and NK cells following alemtuzumab treatment in relapsing-remitting multiple sclerosis
by: Wendy Gilmore, et al.
Published: (2020-06-01)

Alemtuzumab in treatment of chronic lymphocytic leukemia
by: S. S. Bessmeltsev, et al.
Published: (2022-11-01)

Graves' disease following commencement of alemtuzumab therapy: Case report discussing clinical considerations and possible pathophysiology
by: Joel Victor Conway
Published: (2022-09-01)

Consenso de expertos sobre el uso de alemtuzumab en la práctica clínica diaria en España
by: J.E. Meca-Lallana, et al.
Published: (2022-10-01)

Risk of secondary autoimmune diseases with alemtuzumab treatment for multiple sclerosis: a systematic review and meta-analysis
by: Jianguo Yang, et al.
Published: (2024-04-01)

Diffuse alveolar hemorrhage during alemtuzumab infusion in a patient with multiple sclerosis: a case report
by: Aija Zuleron Myro, et al.
Published: (2018-11-01)

Glomerulonephritis after Alemtuzumab Treatment for Multiple Sclerosis: A Report of Two Cases
by: Abdullah Almuhaiteeb, et al.
Published: (2024-04-01)

Autoimmune Encephalitis and CSF Anti-GluR3 Antibodies in an MS Patient after Alemtuzumab Treatment
by: Maria Chiara Buscarinu, et al.
Published: (2019-10-01)

A case of lung injury resembling diffuse pulmonary hemorrhage after the first administration of alemtuzumab in a patient with multiple sclerosis. Role of the HRCT
by: Gaia Cipolla, et al.
Published: (2020-07-01)

Alemtuzumab infusion-associated reactions and laboratory changes in patients with relapsing-remitting multiple sclerosis at baseline and first-year follow-up
by: Furkan Saridas, et al.
Published: (2024-03-01)

Very late-onset membranous nephropathy secondary to alemtuzumab in a patient with multiple sclerosis
by: Z.F. Anabel, et al.
Published: (2024-07-01)

Rhodococcus equi Infection after Alemtuzumab Therapy for T-cell Prolymphocytic Leukemia
by: Jan J. Meeuse, et al.
Published: (2007-12-01)

Immune Regulatory Cell Bias Following Alemtuzumab Treatment in Relapsing-Remitting Multiple Sclerosis
by: Nicole Kashani, et al.
Published: (2021-10-01)

Mycobacterium haemophilum Infection after Alemtuzumab Treatment
by: Mini Kamboj, et al.
Published: (2008-11-01)

Long-Term Effects of Alemtuzumab on CD4+ Lymphocytes in Multiple Sclerosis Patients: A 72-Month Follow-Up
by: Simona Rolla, et al.
Published: (2022-02-01)

Immune reconstitution following alemtuzumab therapy is characterized by exhausted T cells, increased regulatory control of proinflammatory T cells and reduced B cell control
by: Marina Rode von Essen, et al.
Published: (2023-09-01)

Alopecia Universalis following Alemtuzumab Treatment in Multiple Sclerosis: A Barely Recognized Manifestation of Secondary Autoimmunity—Report of a Case and Review of the Literature
by: Julian Zimmermann, et al.
Published: (2017-10-01)